India Introduces 7-Minute Immunotherapy Shot for Lung Cancer Patients
India: A major advancement in cancer care has arrived in India with the launch of Tecentriq SC (atezolizumab) by Roche Pharma India, a subcutaneous immunotherapy for patients with non-small cell lung cancer (NSCLC) that can be administered in just seven minutes. The new formulation represents a significant alternative to conventional intravenous (IV) infusions, which often require several hours in hospital settings, and may help reduce treatment burden for both patients and healthcare facilities.
The newly launched subcutaneous formulation of atezolizumab delivers immunotherapy in just seven minutes while maintaining its clinical effectiveness. The drug blocks the PD-L1 pathway, helping the immune system recognize and attack cancer cells more effectively.
The shorter administration time is also expected to improve efficiency in oncology units by reducing hospital wait times and optimizing the use of infusion facilities. Doctors estimate that several patients can now be treated in the time previously needed for a single IV infusion session.
The approval of the subcutaneous version in India was supported by clinical evidence, including the IMscin001 study, which demonstrated that the drug’s exposure levels are comparable to the intravenous formulation. Importantly, the efficacy and safety profiles were found to be similar across both delivery methods, indicating that the faster injection does not compromise treatment quality.
Another supportive study, IMscin002, highlighted strong patient acceptance of the subcutaneous option. A majority of patients reported preferring the shorter injection-based administration over traditional IV therapy, largely due to reduced time spent in clinical settings and lower treatment-related stress. This preference also reflects a broader shift toward patient-centric cancer care models that prioritize comfort and convenience without compromising clinical outcomes.
In addition to improving patient experience, the innovation is expected to ease the operational load on oncology departments. Reduced dependency on infusion chairs and IV preparation logistics allows healthcare professionals to focus more on clinical decision-making and patient monitoring. Experts believe this may also support the decentralization of cancer care, enabling more treatment centres across India to manage complex therapies efficiently.
The therapy is primarily indicated for patients with NSCLC, one of the most common forms of lung cancer. While the treatment offers a more convenient administration route, it comes at a substantial cost, with each dose priced at approximately ₹3.7 lakh, and multiple cycles required depending on the treatment regimen.
Tecentriq (atezolizumab) is already known in oncology practice, having earlier been introduced in intravenous form in India in 2019 for certain lung cancer indications, including extensive-stage small cell lung cancer in combination with chemotherapy. The latest subcutaneous version builds on this foundation, representing an evolution in delivery rather than a change in mechanism.
Overall, the introduction of a seven-minute immunotherapy injection is being viewed as a significant step forward in lung cancer management in India, combining clinical effectiveness with greater convenience for patients and healthcare systems alike.
Next Story